Your browser doesn't support javascript.
loading
Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu-octreotate peptide radionuclide therapy.
Kennedy, Kim R; Turner, John Harvey; MacDonald, William B G; Claringbold, Phillip G; Boardman, Glenn; Ransom, David T.
Afiliación
  • Kennedy KR; Fiona Stanley Hospital, Cancer Centre, Murdoch, Western Australia, Australia.
  • Turner JH; Fiona Stanley Hospital, Cancer Centre, Murdoch, Western Australia, Australia.
  • MacDonald WBG; Fiona Stanley Hospital, Cancer Centre, Murdoch, Western Australia, Australia.
  • Claringbold PG; Fiona Stanley Hospital, Cancer Centre, Murdoch, Western Australia, Australia.
  • Boardman G; Fiona Stanley Hospital, Cancer Centre, Murdoch, Western Australia, Australia.
  • Ransom DT; Fiona Stanley Hospital, Cancer Centre, Murdoch, Western Australia, Australia.
Cancer ; 128(11): 2182-2192, 2022 06 01.
Article en En | MEDLINE | ID: mdl-35363879
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) has shown favorable results in neuroendocrine tumors (NETs). Long-term safety and efficacy data for 177 Lu-octreotate PRRT, particularly in combination with chemotherapy, is lacking. METHODS: The authors conducted a retrospective review of the long-term toxicity and survival outcomes of 104 patients with advanced NETs treated on 4 phase 2 clinical trials with Lutetium-177-octreotate (177 Lu-octreotate) PRRT, mostly in combination with chemotherapy. Median follow-up was 68 months, which represents the longest follow-up study of 177 Lu-octreotate PRRT for NETs to date. RESULTS: Median progression-free survival (PFS) was 37 months, and median overall survival (OS) was 71 months. Five- and 10-year OS were 62% and 29%, and 5- and 10-year PFS were 36% and 21%, respectively, demonstrating 177 Lu-octreotate can provide durable responses. PRRT was well tolerated with 1.9% of patients developing chronic renal impairment and 1% of patients developing long-term thrombocytopenia. Interestingly, there was a relatively high rate of myelodysplasia (MDS)/leukemia (6.7%), possibly attributable to the longer follow-up (with all except 1 case occurring more than 4 years after PRRT treatment) or to the addition of concurrent chemotherapy. CONCLUSIONS: Lutetium-177-Octreotate PRRT remains an efficacious and well tolerated treatment in long-term follow-up. For clinicians deciding on the timing of PRRT for individual patients, the 6.7% long-term risk of MDS/leukemia needs to be balanced against the 21% PFS at 10 years.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Organometálicos / Leucemia / Tumores Neuroendocrinos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Organometálicos / Leucemia / Tumores Neuroendocrinos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos